Market News

Auxilium Pharmaceuticals Inc. (AUXL)

Jefferies & Co initiated coverage for Auxilium Pharmaceuticals Inc. with a recommendation of Buy.

Dec 17 · 8:27:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Arena Pharmaceuticals Inc. (ARNA)

Jefferies & Co initiated coverage for Arena Pharmaceuticals Inc. with a recommendation of Hold.

Dec 17 · 8:26:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Amylin Pharmaceuticals Inc. (AMLN)

Jefferies & Co initiated coverage for Amylin Pharmaceuticals Inc. with a recommendation of Buy.

Dec 17 · 8:25:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Astrazeneca PLC (AZN)

AstraZeneca and the University of Virginia in Charlottesville Tuesday announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).
http://www.prnewswire.com/news-releases/astrazeneca-and-the-university-of-virginia-sign-strategic-research-collaboration-to-develop-novel-treatments-for-cardiovascular-disease-79304982.html

Dec 15 · 10:42:00 AM
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Gilead Sciences (GILD)

U.S. Food and Drug Administration staff cited concerns on Tuesday with the design and analysis of clinical studies intended to support the effectiveness of Gilead Sciences's experimental cystic fibrosis drug.
"There are concerns that assumptions used in the analysis could have been determined retrospectively," the staff said in their 48-page briefing document.

Dec 8 · 3:17:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Gilead Sciences (GILD)

Gilead Sciences has filed an appeal in the Indian Intellectual Property Appellate Board (IPAB) to challenge a recent order by an Indian Patent Office that rejected two patent claims for its best seller drug Viread (tenofovir disoproxil fumarate).
In August, the Indian Patent Office in Delhi rejected two patents sought by the firm for Viread after patient groups and Indian company Cipla challenged its patentability.

Dec 8 · 3:14:00 PM · Source: The Economic Times
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb and Pfizer announced that the companies are planning to submit an application for regulatory approval of apixaban in Europe for the prevention of venous thromboembolism (VTE) after orthopaedic surgery in the first half of 2010.
The application will be supported by ADVANCE-2 and ADVANCE-3, two clinical trials that evaluated apixaban versus the European dosing regimen of for prevention of VTE in patients undergoing orthopaedic surgery.

Dec 7 · 4:26:00 PM · Source: Pharmabiz.com · Related: Pfizer
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Amgen (AMGN)

Amgen announced that its Board of Directors has authorized repurchases of up to an additional $5 billion in Amgen common stock.
Amgen currently has approximately $1.2 billion remaining under its previous stock repurchase authorization.

Dec 7 · 4:07:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Previous · Next